Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ELYM NASDAQ:RGNX NASDAQ:RNTX NASDAQ:ZURA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELYMEliem Therapeutics$11.44+4.9%$9.85$2.35▼$11.55$340.36M-0.39486,688 shs858,993 shsRGNXREGENXBIO$6.66+6.1%$7.98$5.45▼$16.19$344.31M1.041.67 million shs903,377 shsRNTXRein Therapeutics$0.96+3.5%$1.27$0.89▼$2.18$81.94M1.35471,305 shs721,485 shsZURAZura Bio$3.70+3.4%$4.81$1.00▼$7.44$351.06M0.03896,008 shs472,160 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELYMEliem Therapeutics+1.02%+4.50%-2.33%+55.19%+696.35%RGNXREGENXBIO+6.05%+9.54%-33.67%-22.29%-34.71%RNTXRein Therapeutics+3.49%+1.57%-17.42%-26.32%-50.88%ZURAZura Bio+3.35%+8.82%-22.92%-40.03%+193.65%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELYMEliem Therapeutics$11.44+4.9%$9.85$2.35▼$11.55$340.36M-0.39486,688 shs858,993 shsRGNXREGENXBIO$6.66+6.1%$7.98$5.45▼$16.19$344.31M1.041.67 million shs903,377 shsRNTXRein Therapeutics$0.96+3.5%$1.27$0.89▼$2.18$81.94M1.35471,305 shs721,485 shsZURAZura Bio$3.70+3.4%$4.81$1.00▼$7.44$351.06M0.03896,008 shs472,160 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELYMEliem Therapeutics+1.02%+4.50%-2.33%+55.19%+696.35%RGNXREGENXBIO+6.05%+9.54%-33.67%-22.29%-34.71%RNTXRein Therapeutics+3.49%+1.57%-17.42%-26.32%-50.88%ZURAZura Bio+3.35%+8.82%-22.92%-40.03%+193.65%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELYMEliem Therapeutics 0.00N/AN/AN/ARGNXREGENXBIO 2.73Moderate Buy$23.55253.54% UpsideRNTXRein Therapeutics 2.00Hold$7.00630.77% UpsideZURAZura Bio 2.67Moderate Buy$10.75190.54% UpsideCurrent Analyst Ratings BreakdownLatest RNTX, ZURA, RGNX, and ELYM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/8/2026RGNXREGENXBIO Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/5/2026RGNXREGENXBIO HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $26.006/1/2026RNTXRein Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $8.005/15/2026RGNXREGENXBIO Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$16.005/15/2026RGNXREGENXBIO BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$37.00 ➝ $12.005/15/2026RGNXREGENXBIO Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$25.00 ➝ $14.004/8/2026ZURAZura Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/23/2026ZURAZura Bio Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00 ➝ $11.003/20/2026ZURAZura Bio OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$16.00 ➝ $15.00(Data available from 6/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELYMEliem TherapeuticsN/AN/AN/AN/A$3.90 per shareN/ARGNXREGENXBIO$170.44M2.02N/AN/A$2.03 per share3.28RNTXRein TherapeuticsN/AN/A$0.06 per share16.75($1.07) per shareN/AZURAZura BioN/AN/AN/AN/A$1.38 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELYMEliem Therapeutics-$35.12M-$0.53N/AN/AN/AN/A-47.03%-45.97%N/ARGNXREGENXBIO-$193.88M-$5.60N/AN/AN/A-330.23%-232.50%-61.02%8/6/2026 (Estimated)RNTXRein Therapeutics-$49.87M-$1.90N/AN/AN/AN/A-510.35%-68.14%N/AZURAZura Bio-$99.35M-$1.09N/AN/AN/AN/A-55.74%-48.07%8/13/2026 (Estimated)Latest RNTX, ZURA, RGNX, and ELYM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026RNTXRein Therapeutics-$0.49-$0.19+$0.30-$0.19N/AN/A5/14/2026Q1 2026RGNXREGENXBIO-$1.36-$1.72-$0.36-$1.72$25.84 million$6.39 million5/7/2026Q1 2026ZURAZura Bio-$0.17-$0.22-$0.05-$0.22N/AN/A3/16/2026Q4 2025ZURAZura Bio-$0.18-$0.49-$0.31-$0.49N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthELYMEliem TherapeuticsN/AN/AN/AN/AN/ARGNXREGENXBION/AN/AN/AN/AN/ARNTXRein TherapeuticsN/AN/AN/AN/AN/AZURAZura BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELYMEliem TherapeuticsN/A60.4160.41RGNXREGENXBION/A2.622.62RNTXRein TherapeuticsN/A0.400.40ZURAZura BioN/A19.3319.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELYMEliem Therapeutics69.76%RGNXREGENXBIO88.08%RNTXRein Therapeutics90.89%ZURAZura Bio61.14%Insider OwnershipCompanyInsider OwnershipELYMEliem Therapeutics4.70%RGNXREGENXBIO14.22%RNTXRein Therapeutics5.10%ZURAZura Bio14.23%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableELYMEliem Therapeutics929.75 million28.35 millionNot OptionableRGNXREGENXBIO37051.70 million44.35 millionOptionableRNTXRein Therapeutics985.54 million81.18 millionN/AZURAZura Bio394.88 million81.38 millionOptionableRNTX, ZURA, RGNX, and ELYM HeadlinesRecent News About These CompaniesZura Bio (ZURA) Gets a Buy from OppenheimerJune 13 at 7:34 AM | theglobeandmail.comZura Bio Limited (NASDAQ:ZURA) Receives $10.75 Average PT from BrokeragesJune 8, 2026 | americanbankingnews.comHere's Why We're Not Too Worried About Zura Bio's (NASDAQ:ZURA) Cash Burn SituationJune 3, 2026 | finance.yahoo.comZura Bio Announces Board Resignation, Governance Stability AffirmedMay 22, 2026 | tipranks.comAnalysts Are Bullish on These Healthcare Stocks: Silence Therapeutics (SLN), Zura Bio (ZURA)May 11, 2026 | theglobeandmail.comZura Bio Reports First Quarter 2026 Financial Results and Recent Corporate UpdatesMay 7, 2026 | businesswire.comZura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 4, 2026 | businesswire.comZura Bio Limited Class AApril 24, 2026 | edition.cnn.comOne Zura Bio Insider Raised Their Stake In The Previous YearApril 23, 2026 | finance.yahoo.comPiper Sandler Reaffirms Their Buy Rating on Zura Bio (ZURA)April 16, 2026 | theglobeandmail.comZura Bio: Momentum Is Real, But TibuSHIELD Needs To DeliverMarch 31, 2026 | seekingalpha.comZura Bio Reports Full Year 2025 Financial Results and Recent Corporate UpdatesMarch 19, 2026 | businesswire.comZura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World CongressMarch 5, 2026 | businesswire.comInsider Buying: Zura Bio (NASDAQ:ZURA) Major Shareholder Acquires 2,000,000 Shares of StockMarch 3, 2026 | insidertrades.comZura Bio to Participate in Upcoming Investor ConferencesMarch 2, 2026 | businesswire.comZura Bio Raises $144 Million To Advance Autoimmune Drug PipelineFebruary 27, 2026 | ventureburn.comVZura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesFebruary 27, 2026 | businesswire.comZura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded WarrantsFebruary 25, 2026 | businesswire.comZura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded WarrantsFebruary 24, 2026 | finance.yahoo.comZura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D.February 23, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRNTX, ZURA, RGNX, and ELYM Company DescriptionsEliem Therapeutics NASDAQ:ELYM$11.44 +0.53 (+4.86%) As of 06/12/2026Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.REGENXBIO NASDAQ:RGNX$6.66 +0.38 (+6.05%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$6.57 -0.09 (-1.35%) As of 06/12/2026 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.Rein Therapeutics NASDAQ:RNTX$0.96 +0.03 (+3.49%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$0.96 +0.00 (+0.43%) As of 06/12/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.Zura Bio NASDAQ:ZURA$3.70 +0.12 (+3.35%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$3.68 -0.02 (-0.49%) As of 06/12/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution TJX: Retail’s Apex Predator Feasts on Inflation Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears This Energy Stock Has Quietly Soared 130% in a Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
